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Abstract
Background: Cytokines play an important role in the pathogenesis of pulmonary tuberculosis (PTB) - Type 2 diabetes
mellitus co-morbidity. However, the cytokine interactions that characterize PTB coincident with pre-diabetes (PDM) are not
known.
Methods: To identify the influence of coincident PDM on cytokine levels in PTB, we examined circulating levels of a panel of
cytokines in the plasma of individuals with TB-PDM and compared them with those without PDM (TB-NDM).
Results: TB-PDM is characterized by elevated circulating levels of Type 1 (IFNc, TNFa and IL-2), Type 17 (IL-17A and IL-17F)
and other pro-inflammatory (IL-1b, IFNb and GM-CSF) cytokines. TB-PDM is also characterized by increased systemic levels of
Type 2 (IL-5) and regulatory (IL-10 and TGFb) cytokines. Moreover, TB antigen stimulated whole blood also showed
increased levels of pro-inflammatory (IFNc, TNFa and IL-1b) cytokines as well. However, the cytokines did not exhibit any
significant correlation with HbA1C levels or with bacterial burdens.
Conclusion: Our data reveal that pre-diabetes in PTB individuals is characterized by heightened cytokine responsiveness,
indicating that a balanced pro and anti - inflammatory cytokine milieu is a feature of pre-diabetes - TB co-morbidity.
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Introduction
Pre-diabetes (PDM) or intermediate hyperglycemia is a high risk
state for diabetes that is defined by glycemic variables that are
higher than normal, but lower than diabetic thresholds [1]. The
prevalence of PDM is increasing worldwide, and it is estimated
that over 470 million people will have PDM by 2030 [2]. PDM is
associated with the simultaneous presence of insulin resistance and
pancreatic beta-cell dysfunction - abnormalities that start before
changes in glycemic control are detectable [1,3]. Observational
evidence shows associations between PDM and early forms of
complications known to occur in typical diabetes including
nephrophathy, small fiber neuropathy, retinopathy and macro-
vascular disease [1,3]. Typically 5–10% of individuals with PDM
become diabetic every year, although the conversion rates vary
with population characteristics and definition of PDM [4,5].
Type 2 DM is one of the major risk factors for the development
of active pulmonary tuberculosis (PTB) and this interaction is
typically characterized by elevated systemic levels of pro-inflam-
matory cytokines especially Type 1 and Type 17 cytokines [6,7],
cytokines that appear to play an important role in pathogenesis.
Whether PDM is also associated with increased susceptibility to
active PTB or whether this interaction is associated with a
dysregulated cytokine environment is not known. Epidemiological
studies have shown a high prevalence of PDM in PTB [8,9]. In
one study from India, a country with extremely high burdens of
both TB and DM, it was shown that among newly diagnosed TB
patients, 25% had DM while another 25% had PDM, numbers
that are in stark contrast to DM and PDM in the general
population where the prevalences are 10% and 8%, respectively
[8]. Since DM is not only associated with an increased risk of
developing active TB but also with TB disease severity and
treatment outcomes [10], it stands to reason that PDM might also
potentially have an impact on the outcome of PTB.
In this study, we sought to delineate the influence of PDM on
the systemic and antigen -specific cytokine response in patients
newly diagnosed with active PTB. We focused on a large panel of
Type 1, Type 2, Type 17, regulatory and other pro –
inflammatory cytokines in plasma and TB antigen-stimulated
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whole blood from individuals with active TB and coincident PDM
(TB-PDM) and compared these to those with active TB but
without pre-diabetes (TB-NDM). We show that the pre-diabetic
state at the time of PTB causes systemic increases in the levels of
most of the pro – and anti – inflammatory cytokines, some
appearing to be TB antigen-induced. Thus, our data suggest that
heightened cytokine levels in active PTB may be associated with
even moderate glycemic control.
Materials and Methods
Ethics statement
All individuals were examined as part of a natural history study
protocol approved by the Institutional Review Board of the
National Institute of Research in Tuberculosis (NCT01154959),
and informed written consent was obtained from all participants.
Study Population
We studied a group of 90 individuals with active PTB attending
the TB Clinic at Stanley Medical Hospital, Chennai, India.
Patients were prospectively/consecutively enrolled with 48 having
PDM and 42 having normal HbA1c levels (NDM). PTB was
diagnosed on the basis of sputum smear and culture positivity.
Bacterial burdens were assessed by measuring smear grades
following Ziehl-Nielsen staining of sputum smears. PDM was
diagnosed on the basis of glycated hemoglobin (HbA1c) levels,
according to the American Diabetes Association criteria (all PDM
individuals had HbA1c levels between 5.7 and 6.4%). All the
individuals were HIV seronegative. The two groups did not differ
significantly in terms of the sputum smear grade. All individuals
were anti-tuberculous treatment naı¨ve. Anthropometric measure-
ments, including height, weight, and waist circumference, and
biochemical parameters, including random plasma glucose, fasting
lipid profile and HbA1c were obtained using standardized
techniques as detailed elsewhere [11].
ELISA
Plasma cytokines and chemokines were measured using a
Bioplex multiplex cytokine assay system (Bio-Rad, Hercules, CA).
The parameters analyzed were IFNc, TNFa, IL-2, IL-17A, IL-4,
IL-5, IL-10, IL-6, IL-12 and GM-CSF. Plasma levels of TGFb, IL-
1a, IL-1b (all R& D Systems); IL-17F (Biolegend); IL-22
(eBioscience); Type 1 interferons (IFNs) - IFNa (multiple subtypes)
and IFNb (PBL Interferon Source) were measured by ELISA.
Quantiferon supernatant ELISA
Whole blood from a subset of TB-PDM and TB-NDM
individuals (n = 22 each) was incubated with either no antigen or
TB antigen (ESAT-6, CFP-10, TB 7.7) according to the
manufacturers instructions using the Quantiferon in Tube Gold
kit. The unstimulated or TB antigen stimulated whole blood
supernatants were then used to analyze the levels of IFNc, TNFa,
IL-17A and IL-1b using the Duo-set ELISA kits from R& D
systems.
Ex vivo analysis
All antibodies used in the study were from BD Biosciences/BD
Pharmingen/eBioscience/R&D systems. Whole blood was used
for ex vivo phenotyping and it was performed on all 90 individuals.
Naı¨ve and memory T cell phenotyping was performed using
CD45RA and CCR7 staining on CD4+ and CD8+ T cells and
natural regulatory T cell (nTregs) phenotyping using CD25, Foxp3
and CD127. A representative graph showing the gating strategy
for CD4+ and CD8+ T cell subsets is depicted in Figure S1.
Statistical Analysis
Geometric means (GM) were used for measurements of central
tendency. Statistically significant differences between two groups
were analyzed using the nonparametric Mann-Whitney U test
followed by Holm’s correction for multiple comparisons. Corre-
lations were calculated using Spearman rank correlation. Analyses
were performed using GraphPad PRISM Version 5.01.
Results
Study population characteristics
The baseline characteristics including demographic and bio-
chemical features of the study population are shown in Table 1. As
can be seen, compared to subjects without pre-diabetes (TB-
NDM), those with pre-diabetes and TB (TB-PDM) had higher
glycated hemoglobin but did not differ significantly in other
biochemical parameters including random blood glucose, serum
cholesterol, HDL, LDL and triglycerides levels. In addition, the
baseline immunological profile reveals significantly lower frequen-
cies of CD4+ regulatory T cells (p = 0.0009) and significantly
higher frequencies of CD8+ effector memory T cells (p = 0.0047) in
TB-PDM individuals.
TB-PDM is associated with increased circulating levels of
Type 1 and Type 17 cytokines
To determine the influence of PDM on Type 1 and Type 17
cytokines in active PTB, we measured the circulating levels of IFN-
c, TNFa and IL-2 as well as IL-17A, IL-17F and IL-22 in TB-
PDM and TB-NDM individuals (Figure 1). As shown in
Figure 1A, the systemic levels of all three Type 1 cytokines –
IFNc (Geometric Mean of 335.9 pg/ml in TB-PDM versus
169.2 pg/ml in TB-NDM), TNFa (GM of 338.4 pg/ml vs.
252.4 pg/ml) and IL-2 (GM of 25.1 pg/ml vs. 13.9 pg/ml) were
significantly higher in TB-PDM compared to TB-NDM individ-
uals. Similarly, the systemic levels of the prototypical Type 17
cytokines – IL-17A (GM of 106.3 pg/ml vs. 90.6 pg/ml) and IL-
17F (GM of 202.8 pg/ml vs. 138.1 pg/ml) were also significantly
higher in TB-PDM compared to TB-NDM individuals. In
contrast, no significant differences in IL-22 levels were found
between the two groups. Thus, TB-PDM is associated with
heightened levels of Type 1 and Type 17 at the time of
presentation of active PTB.
TB-PDM is associated with increased circulating levels of
Type 2 and regulatory cytokines
To determine the influence of PDM on Type 2 and regulatory
cytokines in active TB, we measured the circulating levels of IL-4
and IL-5 as well as IL-10 and TGFb in TB-PDM and TB-NDM
individuals (Figure 1). As shown in Figure 1B, the systemic levels
of IL-5 (GM of 72.1 pg/ml vs. 46.1 pg/ml) were significantly
higher in TB-PDM compared to TB-NDM individuals. Similarly,
the systemic levels of the regulatory cytokines - IL-10 (GM of
61.6 pg/ml vs. 36.3 pg/ml) and TGFb (GM of 398.2 pg/ml vs.
295.6 pg/ml) were also significantly higher in TB-PDM compared
to TB-NDM individuals. Thus, TB-PDM is not associated with a
concomitant decrease of Type 2 or regulatory cytokine levels at the
time of presentation with active PTB.
TB-PDM is associated with increased circulating levels of
other pro-inflammatory cytokines
To determine the influence of PDM on the IL-1 family and
other pro-inflammatory cytokines as well as Type 1 IFNs in active
TB, we measured circulating levels of these in TB-PDM and
Cytokines in Tuberculosis with Pre-Diabetes
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TB-NDM individuals (Figure 1). As shown in Figure 1C, the
systemic levels of IL-1b (GM of 195 pg/ml vs. 140.1 pg/ml) and
GM-CSF (GM of 61.8 pg/ml vs. 50.9 pg/ml) were significantly
higher in TB-PDM compared to TB-NDM individuals. In
contrast, the systemic levels of IL-1a, IL-6 and IL-12 were not
significantly different between the two groups. Similarly, the levels
of IFNb (GM of 488.3 pg/ml vs. 220.5 pg/ml) but not IFNa were
found be present at significantly higher levels in TB-PDM
compared to TB-NDM individuals. Thus, TB-PDM is associated
with heightened levels of pro-inflammatory cytokines at the time of
presentation.
TB-PDM is associated with increased TB antigen
stimulated levels of pro-inflammatory cytokines
To determine the influence of PDM on TB antigen stimulated
cytokine production in active PTB, we measured circulating levels
of these cytokines following stimulation of whole blood with no
antigen or a cocktail of TB antigens (ESAT-6, CFP-10, TB 7.7) in
a subset (n = 22 each) of TB-PDM and TB-NDM individuals
(Figure 2). As shown in Figure 2A, the spontaneously produced
levels of the IFNc (GM of 70.1 pg/ml vs. 34.8 pg/ml), TNFa (GM
of 69.7 pg/ml vs. 35.6 pg/ml) and IL-1b (GM of 64.4 pg/ml vs.
44.5 pg/ml) were significantly higher in TB-PDM compared to
TB-NDM individuals. Similarly, as shown in Figure 2B, the TB
antigen stimulated levels of IFNc (GM of 278.8 pg/ml vs.
120.1 pg/ml), TNFa (GM of 67.2 pg/ml vs. 42.5 pg/ml) and
IL-1b (GM of 65.9 pg/ml vs. 43.1 pg/ml) were also significantly
higher in TB-PDM compared to TB-NDM individuals. Thus, TB-
PDM is associated with heightened levels of TB antigen stimulated
pro-inflammatory cytokines.
No relationship between systemic cytokines and HbA1c
levels or with bacterial burdens
Since HbA1c is an accurate indicator of the level of glycemic
control and increased values reflect poor control, we sought to
examine the relationship between the systemic levels of Type 1,
Type 17 and other pro-inflammatory cytokines with the degree of
glycemic control. To this end, we assessed the association of IFNc,
TNFa, IL-2, IL-17A, IL-17F, IL-22, IL-1b, GM-CSF and IL-12
with HbA1C levels (in %) in the PDM individuals in the study. As
shown in Figure 3, we observed no significant correlation between
systemic cytokine levels and the HbA1c levels in TB-PDM
individuals.
Since smear grades are an accurate reflection of bacterial
burdens, we also sought to examine the relationship between the
systemic levels of Type 1, Type 17 and other pro-inflammatory
cytokines with the bacterial burdens in the TB-PDM individuals.
As shown in Figure 4, we observed no significant correlation
between the circulating levels of IFNc, TNFa, IL-2, IL-17A, IL-
17F, IL-10, IL-1b, IFNb and TGFb.
Thus, systemic levels of cytokines in TB-PDM do not reflect
poor glycemic controls or increased bacterial burdens.
Discussion
PDM prevalence is increased in TB – it is presently unknown
whether TB is causing PDM in susceptible individuals, or if PDM
increases susceptibility to TB. Either possibility would have
significant public health implications [12,13]. If PDM impairs
host defense and increases the risk for progression from LTBI to
active TB, then the TB burden attributable to metabolic
syndromes would be far greater than current estimates. It would
also imply the existence of distinct susceptibility mechanisms
Table 1. Demographics, biochemistry and immunology profile of TB-PDM and TB-NDM individuals.
Study Demographics PTB-PDM PTB-NDM P value
Age (yrs) 42.5 (18–65) 39.5 (20–65) NS
Sex M/F 38/10 36/6 NS
BMI (kg/m2) 22.5 (16.4–24.5) 20.4 (14.6–22.3) NS
Glycated Hemoglobin(%) 5.92 (5.71–6.44) 5.25 (4.04–5.65) NS
Random glucose (mg/dl) 99 (66–161) 100 (78–156) NS
Total cholesterol (mg/dl) 168 (142–202) 146 (124–205) NS
Serum triglycerides (mg/dl) 102 (64–424) 98 (56–384) NS
High density lipoprotein cholesterol (ml/dl) 37 (29–59) 42 (25–66) NS
Low density lipoprotein cholesterol (ml/dl) 104 (44–180) 96 (52–146) NS
Immunological Parameters
CD4+ Naı¨ve Cells (CD45RA+CCR7+) 37.5(10–77) 34(11–67) NS
CD4+ Central Memory Cells (CD45RA-CCR7+) 32(11–86) 27.5(15–64) NS
CD4+ Effector Memory Cells (CD45RA-CCR7-) 24.05(10–55) 29.5(9–62) NS
CD4+ Regulatory T Cells (CD25+FoxP3+CD127dim) 3.3015(2.129–7.798) 4.659(1.968–9.295) p = 0.0009
CD8+ Naı¨ve Cells (CD45RA+CCR7+) 28(18–48) 25(10–69) NS
CD8+ Central Memory Cells (CD45RA-CCR7+) 1.75(0.9–7.9) 1.1(0.5–7.1) p = 0.0047
CD8+ Effector Memory Cells (CD45RA-CCR7-) 34.5(10–81) 30(11–79) NS
The values represent geometric means and range (except for age where median and range are shown). P values were calculated using the Mann-Whitney test (except
for sex which was tested by Fishers exact test).
doi:10.1371/journal.pone.0112108.t001
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Figure 1. Elevated systemic levels of Type 1, Type 2 and other pro-inflammatory and regulatory cytokines in TB-PDM. The plasma
levels of Type 1 (IFNc, TNFa, IL-2); Type 17 (IL-17A, IL-17F and IL-22) cytokines (A) and Type 2 (IL-4, IL-5, IL-13); regulatory (IL-10 and TGFb) cytokines
(B) and other pro-inflammatory (IL-1a, IL-1b, IFNa, IFNb, IL-6, IL-12 and GM-CSF) were measured by ELISA in TB-PDM (n = 48) and TB-NDM (n = 42)
individuals. The data are represented as scatter plots with each circle representing a single individual (light grey – PDM and dark grey – NDM). P
values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pone.0112108.g001
Figure 2. Elevated TB antigen stimulated and unstimulated levels of IFNc, TNFa, IL-17A and IL-1b in TB-PDM. The unstimulated (A) or
TB antigen stimulated (B) levels of IFNc, TNFa, IL-17A and IL-1b were measured by ELISA in whole blood of a subset of TB-PDM (n = 22) and TB-NDM
(n = 22) individuals. The data are represented as scatter plots with each circle representing a single individual (light grey – PDM and dark grey – NDM).
P values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pone.0112108.g002
Cytokines in Tuberculosis with Pre-Diabetes
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unrelated to hyperglycemia but likely shared in PDM and type 2
DM. Alternatively, TB disease might promote insulin resistance
and induce PDM as a consequence of inflammatory stress. In that
scenario, TB would represent a significant factor contributing to
disordered glucose metabolism with implications for bidirectional
screening [14,15]. It would then be important to learn whether
this is a transient or persistent effect and whether TB can push pre-
diabetics to full DM with all of its negative consequences.
Inflammation - induced inhibition of the insulin signaling
pathway can lead to insulin resistance and contribute to the
development of Type 2 DM [16]. Pre-diabetes and insulin
resistance are associated with a chronic but subclinical inflamma-
tory process that impairs insulin action in most tissues and could
also hamper pancreatic beta-cell function [17]. The involvement
of cytokines induced by this inflammation suggest an innate
immune response [18]. Moreover, components of the immune
system are altered in PDM, including altered levels of specific
cytokines and chemokines, changes in the number and activation
state of various immune cell subsets and increased apoptosis and
tissue fibrosis [17]. Together, these changes suggest that inflam-
mation participates in the pathogenesis of PDM but how these
changes affect the immune response to bystander antigens or
newly acquired infections remains unclear [19]. One possible
mechanism is that an impaired immune response in PDM
facilitates either primary infection with tuberculosis or reactivation
of latent tuberculosis [20,21].
Cytokines are known to play a major role in determining the
outcome of mycobacterial infections [22]. However, unbalanced
cytokine responses can also play an important role in promoting
pathology in TB disease [23]. Thus, while Type 1 and Type 17
cytokines typically impart protection against TB infection [24],
excess of TNFa [25] or IL-17 [26] are known to be associated with
deleterious effects in TB disease. Moreover, Type 1 IFN driven
gene expression signatures are considered a characteristic feature
of active TB disease [27] and Type 1 IFNs are known to promote
pathology in both animal models and human disease [28,29]. Our
data clearly reveal that the PDM - TB nexus is characterized by
heightened circulating levels of most of the pro-inflammatory
cytokines. So, contrary to their expected role in host protection,
these cytokines are more likely to be associated with promotion of
pathology in PTB. This is very similar to our previous findings in
overt DM and PTB, where we had observed not only elevated
plasma levels of pro-inflammatory cytokines but also increased TB
antigen - specific Th1 and Th17 cellular and cytokine responses
[6,30].
Figure 3. No relationship between systemic levels of cytokines and HbA1c levels in TB – PDM individuals. The relationship between the
plasma levels of IFNc, TNFa, IL-2, IL-17A, IL-17F, IL-22, GM-CSF, IL-1b and IFNb and HbA1c levels was examined in TB - PDM (n = 48) individuals. The
data are represented as scatter plots with each circle representing a single individual. P values were calculated using the Spearman rank correlation.
doi:10.1371/journal.pone.0112108.g003
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One potential mechanism for the increase in levels of pro-
inflammatory cytokines in TB-PDM individuals could be a
concomitant decrease in the levels of systemic Type 2 or regulatory
cytokines. However, as revealed by the increased systemic levels of
IL-5, IL-10 and TGFb, our data show that even regulatory
cytokines are present at elevated levels in PDM individuals. Since
Type 2 cytokines, IL-10 and TGFb are known down modulators
of inflammatory responses in TB [31,32], this suggests that there is
a compensatory mechanism in place to regulate inflammation in
the setting of PDM. Another possibility is that there is a broad and
possibly unrelated increase in T cell activation responses (reflected
by cytokines) in PDM. Thus, PDM in the context of active PTB is
characterized by a predominantly balanced network of pro - and
anti - inflammatory cytokines, accounting for the lack of
differences in bacterial loads between the 2 groups studied.
Moreover, systemic levels of cytokines do not exhibit any
significant association with bacterial burdens, suggesting that this
dysregulation of cytokine levels is not solely driven by differences
in bacterial burdens.
The major limitation in analyzing the immune parameters in
the circulation is the non – specific nature of the analysis. We have
therefore, sought to corroborate the plasma cytokine results by
measuring the levels of a subset of cytokines in TB antigen
stimulated whole blood supernatants. Our data on the cytokine
responses following TB antigen stimulation clearly show that PDM
has a profound effect and that elevation in circulating levels of
Type 1 cytokines as well as IL-1b is reflected by similar elevations
of in vitro measured cytokines following stimulation with
mycobacterial antigens in TB-DM. Whether the heightened
responsiveness observed in the TB-PDM individuals is specific to
TB infection or is a general phenomenon applicable to different
infections remains to be determined. While our data clearly
provide descriptive data on the interaction between PDM and TB,
future studies are needed to explore the mechanism governing this
important interaction. Our data on the lack of differences in BMI
and lipid metabolism appears to exclude these parameters as
potential confounders (see Table 1). However, other metabolic
mediators including free fatty acids that are known to be induced
in insulin resistance could also play a role in this interaction. In
addition, our data also reveal that the baseline frequencies of
nTregs and CD8+ effector memory T cells are significantly
different between the two groups, thereby making highly unlikely
that significant perturbations in CD4+ or CD8+ T cell numbers are
responsible for the differential cytokine profiles. The cellular
sources of the cytokines produced should provide us clues to the
mechanism behind this differential response. Finally our data
argue that the interaction of active TB with pre-diabetes is in
contrast to that of latent TB with diabetes, since in the latter
Figure 4. No relationship between systemic levels of cytokines and bacterial burdens in TB – PDM individuals. The relationship
between the plasma levels of IFNc, TNFa, IL-2, IL-17A, IL-17F, IL-10, IL-1b, IFNb, TGFb and bacterial burdens (as assessed by smear grades - 1+, 2+ and
3+) was examined in TB - PDM (n = 48) individuals. The data are represented as scatter plots with each circle representing a single individual. P values
were calculated using the Spearman rank correlation.
doi:10.1371/journal.pone.0112108.g004
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scenario, impairment of cytokine secretion is the major finding
[33]. Hence, pre-diabetes interaction with latent TB potentially
enhances susceptibility to TB disease by compromising the
production of protective cytokines, while pre-diabetes interaction
with active TB potentially promotes pathology by enhancing the
production of cytokines.
Our study provides important insights into the influence of pre-
diabetes on the pathogenesis of TB disease. Our data also suggest
that this interaction might also have an effect on TB disease
potentially shifting the balance of metabolic regulation from pre-
diabetes to overt diabetes. These data underlie the need to assess
more systematically – using epidemiological, clinical and immu-
nological studies – the interaction between pre-diabetes and
tuberculosis and suggests that intervention that targets important
innate and adaptive responses may provide new clues to pursue
immunological alternatives as therapeutics for dealing with the
global menace of coincident diabetes and TB.
Supporting Information
Figure S1 Gating strategy for estimating frequencies of
CD4+ and CD8+ naı¨ve, central memory and effector
memory T cells and natural regulatory T cells. (A) A
representative flow cytometry plot showing the gating strategy for
estimation of naı¨ve, central memory and effector memory cells
from CD4+ and CD8+ T cells. Naı¨ve cells were classified as
CD45RA+ CCR7+; effector memory cells as CD45RA- CCR7-;
and central memory cells as CD45RA- CCR7+. (B) A represen-
tative flow cytometry plot showing the gating strategy for
estimation of nTregs from CD4+ T cells. Natural T regulatory T
cells (nTregs) were classified as CD4+, CD25+, Foxp3+,
CD127dim.
(TIFF)
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